|Bid||2.4200 x 4000|
|Ask||2.4400 x 3100|
|Day's Range||2.3850 - 2.5900|
|52 Week Range||0.1500 - 3.4500|
|Beta (5Y Monthly)||3.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.25|
MicroVision (MVIS) closed the most recent trading day at $2.36, moving -1.67% from the previous trading session.
Microvision (NASDAQ: MVIS) reported Q2 sales of $587.00 thousand. Earnings fell to a loss of $2.30 million, resulting in a 57.3% decrease from last quarter. In Q1, Microvision brought in $1.47 million in sales but lost $5.38 million in earnings.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Microvision posted an ROCE of 0.91%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on MVISROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Microvision is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Microvision's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Recap Microvision reported Q2 earnings per share at $-0.02/share, which did not meet analyst predictions of $-0.01/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 12 Technology Stocks Moving In Friday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
REDMOND, Wash., Sept. 17, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc. (Nasdaq:MVIS) announced that Institutional Shareholder Services Inc., (“ISS”), and Glass Lewis recommend that MicroVision shareholders vote to approve the Company proposals described in the Company’s Proxy Statement filed August 25, 2020. ISS and Glass Lewis are leading independent proxy advisory firms relied upon by hundreds of major institutional investment firms and mutual funds. “We are pleased that both ISS and Glass Lewis agree with the Board that a vote to increase the authorized number of shares of the Company’s common stock is in the best interest of the Company as the Company continues to explore strategic alternatives, including the sale of the Company,” said Sumit Sharma, Chief Executive Officer. “Every vote is important and I encourage our shareholders to support the Company by voting to approve the proposals in our Proxy Statement before the Special Meeting of Shareholders on October 8, 2020.”Detailed information about the proposals can be found in the Company’s Proxy Statement. If shareholders have any questions or need assistance voting shares, they can contact the firm assisting the Company in solicitation of proxies: Saratoga Proxy Consulting LLC, at (212) 257-1311 or (888) 368-0379 or firstname.lastname@example.orgAbout MicroVisionMicroVision is the creator of PicoP® scanning technology, an ultra-miniature sensing and projection solution based on the laser beam scanning methodology pioneered by the Company. MicroVision’s platform approach for this sensing and display solution means that its technology can be adapted to a wide array of applications and form factors. We combine our hardware, software, and algorithms to unlock value for our customers by providing them a differentiated advanced solution for a rapidly evolving, always-on world.Extensive research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and has been included in the Ocean Tomo 300 Patent Index. The Company is based in Redmond, Washington.For more information, visit the Company’s website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc or follow MicroVision on Twitter at @MicroVision.MicroVision® and PicoP® are registered trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.Forward-Looking StatementsCertain statements contained in this release, including those relating to benefit of voting to approve proposals in the Proxy Statement, product applications and solutions, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the risk that the Company may not succeed in finding strategic solutions, including a potential sale of the Company, with acceptable timing, benefits or costs; our ability to operate with limited cash or to raise additional capital when needed; market acceptance of our technologies and products or for products incorporating our technologies; the failure of our commercial partners to perform as expected under our agreements, including from the impact of COVID-19; our ability to identify parties interested in paying any amounts or amounts we deem desirable for the purchase or license of intellectual property assets; our or our customers’ failure to perform under open purchase orders, our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; our ability to maintain our listing on the Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect us to a greater extent than indicated. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.Investor Relations Contacts:David H. Allen Darrow Associates, Inc. 408.427.4463 email@example.com